Mirabella Financial Services LLP Trims Stake in Eli Lilly and Company (NYSE:LLY)

Mirabella Financial Services LLP cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 43.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,993 shares of the company's stock after selling 8,297 shares during the period. Mirabella Financial Services LLP's holdings in Eli Lilly and Company were worth $8,487,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. CWA Asset Management Group LLC increased its stake in Eli Lilly and Company by 11.9% during the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after buying an additional 724 shares in the last quarter. Centerpoint Advisory Group acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $514,000. M&T Bank Corp raised its position in shares of Eli Lilly and Company by 0.7% in the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock valued at $236,389,000 after buying an additional 1,867 shares during the last quarter. Kentucky Trust Co purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $834,000. Finally, Proficio Capital Partners LLC grew its stake in Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after acquiring an additional 1,562 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Up 3.4 %

NYSE:LLY traded up $28.51 during midday trading on Thursday, reaching $857.93. The company had a trading volume of 1,467,734 shares, compared to its average volume of 3,425,226. The stock's fifty day simple moving average is $826.81 and its 200-day simple moving average is $819.07. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The firm has a market capitalization of $813.47 billion, a price-to-earnings ratio of 73.07, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on LLY shares. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Truist Financial raised their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Guggenheim dropped their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a report on Monday, April 14th. Finally, StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Two analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,017.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.